Skip to main content
Equibles
CAMP logo

CAMP · Camp4 Therapeutics Corp · Financials

Track CAMP — free

Use CAMP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CAMP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.33 -0.07 (-1.59%) At close · Sep 9
Russell 2000 member Rebalance outlook locked
Market Cap
$277.37M
Shares
62.75M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →
Revenue
$3.5M +436.5%
FY2025 Revenue FY2023–FY2025
Net Income
-$80.4M -55.2%
FY2025 Net Income FY2023–FY2025
Operating Margin
-1502.43% +6639.9pp
FY2025 Operating Margin FY2023–FY2025
Diluted EPS
-$2.65 +76%
FY2025 Diluted EPS FY2023–FY2025
Operating Cash Flow
-$29.55M +35.1%
FY2025 Operating Cash Flow FY2023–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2025 FY2024 FY2023
$4.22M $3.5M $652K $350K
$38.69M $38.2M $38.82M $40.62M
$17.91M $17.36M $14.92M $11.61M
$1.84M $1.64M $1.7M $1.68M
$57.09M $56.05M $53.74M $52.23M
-$52.88M -$52.56M -$53.09M -$51.88M
— -1502.43% -8142.33% -14822.57%
-$51.04M -$50.92M -$51.39M -$50.2M
$2.85M $2.17M $1.33M $2.81M
-$54.37M -$27.85M $1.3M $2.59M
$0 $0 $0 $0
-$107.24M -$80.4M -$51.79M -$49.29M
— -2298.54% -7943.4% -14083.14%
-$107.24M -$80.4M -$51.79M —
-$107.24M -$80.4M -$51.79M -$49.29M
USD/shares -$2.31 -$2.65 -$11.04 -$124.80
USD/shares -$2.31 -$2.65 -$11.04 -$124.80
shares — 30.38M 4.69M 394.98K
shares — 30.38M 4.69M 394.98K
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.

Debt Profile

Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.

Debt data is being processed. Please check back later.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
—
Peer median 7.33×
EV/EBIT
—
Peer median 9.87×
P/E (TTM)
—
Peer median 11.13×

Peer medians compare against the 317 similar-size Biotechnology companies (of 537 listed).

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component FY2025 FY2024 FY2023
RD $3,498,000 $652,000 $350,000
Key facts CIK 1736730 CUSIP 13463J101 13F (30d) 45 filings 45 filers Visit website Investor relations